vs

Side-by-side financial comparison of EyePoint, Inc. (EYPT) and Quanterix Corp (QTRX). Click either name above to swap in a different company.

Quanterix Corp is the larger business by last-quarter revenue ($43.9M vs $619.0K, roughly 70.8× EyePoint, Inc.). Quanterix Corp runs the higher net margin — -52.7% vs -10922.3%, a 10869.6% gap on every dollar of revenue. On growth, Quanterix Corp posted the faster year-over-year revenue change (24.7% vs -94.7%). Quanterix Corp produced more free cash flow last quarter ($-16.5M vs $-66.0M). Over the past eight quarters, Quanterix Corp's revenue compounded faster (16.9% CAGR vs -77.0%).

EyePoint Pharmaceuticals Inc. is a Watertown, Massachusetts company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery.

Quanterix Corp is a life sciences firm that develops, manufactures, and commercializes ultra-sensitive single-molecule detection diagnostic platforms, reagents, and testing services. Its solutions empower biological research, drug development, and clinical diagnostics across oncology, neurodegenerative disorders, infectious diseases, and other therapeutic areas, serving research institutions, biopharmaceutical companies, and clinical laboratories globally.

EYPT vs QTRX — Head-to-Head

Bigger by revenue
QTRX
QTRX
70.8× larger
QTRX
$43.9M
$619.0K
EYPT
Growing faster (revenue YoY)
QTRX
QTRX
+119.4% gap
QTRX
24.7%
-94.7%
EYPT
Higher net margin
QTRX
QTRX
10869.6% more per $
QTRX
-52.7%
-10922.3%
EYPT
More free cash flow
QTRX
QTRX
$49.5M more FCF
QTRX
$-16.5M
$-66.0M
EYPT
Faster 2-yr revenue CAGR
QTRX
QTRX
Annualised
QTRX
16.9%
-77.0%
EYPT

Income Statement — Q4 2025 vs Q4 2025

Metric
EYPT
EYPT
QTRX
QTRX
Revenue
$619.0K
$43.9M
Net Profit
$-67.6M
$-23.1M
Gross Margin
45.7%
Operating Margin
-11364.3%
-56.4%
Net Margin
-10922.3%
-52.7%
Revenue YoY
-94.7%
24.7%
Net Profit YoY
-63.3%
-98.8%
EPS (diluted)
$-0.82
$-0.48

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EYPT
EYPT
QTRX
QTRX
Q4 25
$619.0K
$43.9M
Q3 25
$966.0K
$40.2M
Q2 25
$5.3M
$24.5M
Q1 25
$24.5M
$30.3M
Q4 24
$11.6M
$35.2M
Q3 24
$10.5M
$35.8M
Q2 24
$9.5M
$34.4M
Q1 24
$11.7M
$32.1M
Net Profit
EYPT
EYPT
QTRX
QTRX
Q4 25
$-67.6M
$-23.1M
Q3 25
$-59.7M
$-33.5M
Q2 25
$-59.4M
$-30.0M
Q1 25
$-45.2M
$-20.5M
Q4 24
$-41.4M
$-11.6M
Q3 24
$-29.4M
$-8.4M
Q2 24
$-30.8M
$-7.4M
Q1 24
$-29.3M
$-11.2M
Gross Margin
EYPT
EYPT
QTRX
QTRX
Q4 25
45.7%
Q3 25
42.8%
Q2 25
46.2%
Q1 25
54.1%
Q4 24
63.0%
Q3 24
93.0%
56.3%
Q2 24
85.2%
64.7%
Q1 24
93.5%
57.8%
Operating Margin
EYPT
EYPT
QTRX
QTRX
Q4 25
-11364.3%
-56.4%
Q3 25
-6420.8%
-92.8%
Q2 25
-1166.8%
-151.6%
Q1 25
-199.7%
-86.9%
Q4 24
-390.4%
-42.0%
Q3 24
-311.2%
-32.8%
Q2 24
-364.5%
-31.8%
Q1 24
-285.2%
-47.3%
Net Margin
EYPT
EYPT
QTRX
QTRX
Q4 25
-10922.3%
-52.7%
Q3 25
-6183.4%
-83.3%
Q2 25
-1114.3%
-122.6%
Q1 25
-184.8%
-67.6%
Q4 24
-357.3%
-33.1%
Q3 24
-279.0%
-23.3%
Q2 24
-325.3%
-21.5%
Q1 24
-250.6%
-34.8%
EPS (diluted)
EYPT
EYPT
QTRX
QTRX
Q4 25
$-0.82
$-0.48
Q3 25
$-0.85
$-0.73
Q2 25
$-0.85
$-0.77
Q1 25
$-0.65
$-0.53
Q4 24
$-0.65
$-0.30
Q3 24
$-0.54
$-0.22
Q2 24
$-0.58
$-0.19
Q1 24
$-0.55
$-0.29

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EYPT
EYPT
QTRX
QTRX
Cash + ST InvestmentsLiquidity on hand
$306.1M
$29.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$306.1M
$295.7M
Total Assets
$364.0M
$418.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EYPT
EYPT
QTRX
QTRX
Q4 25
$306.1M
$29.8M
Q3 25
$204.0M
$38.3M
Q2 25
$255.7M
$132.9M
Q1 25
$318.2M
$76.5M
Q4 24
$370.9M
$56.7M
Q3 24
$253.8M
$29.3M
Q2 24
$280.2M
$47.0M
Q1 24
$299.3M
$45.3M
Stockholders' Equity
EYPT
EYPT
QTRX
QTRX
Q4 25
$306.1M
$295.7M
Q3 25
$200.2M
$314.5M
Q2 25
$246.0M
$292.5M
Q1 25
$298.4M
$316.4M
Q4 24
$336.5M
$330.0M
Q3 24
$218.7M
$338.9M
Q2 24
$228.3M
$340.8M
Q1 24
$249.9M
$343.4M
Total Assets
EYPT
EYPT
QTRX
QTRX
Q4 25
$364.0M
$418.8M
Q3 25
$251.7M
$444.1M
Q2 25
$301.1M
$375.6M
Q1 25
$362.6M
$396.5M
Q4 24
$418.5M
$406.5M
Q3 24
$300.9M
$411.0M
Q2 24
$324.2M
$415.9M
Q1 24
$329.2M
$414.2M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EYPT
EYPT
QTRX
QTRX
Operating Cash FlowLast quarter
$-65.0M
$-16.4M
Free Cash FlowOCF − Capex
$-66.0M
$-16.5M
FCF MarginFCF / Revenue
-10667.7%
-37.7%
Capex IntensityCapex / Revenue
159.3%
0.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-243.4M
$-80.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EYPT
EYPT
QTRX
QTRX
Q4 25
$-65.0M
$-16.4M
Q3 25
$-59.4M
$-41.2M
Q2 25
$-62.6M
$-5.7M
Q1 25
$-53.1M
$-13.9M
Q4 24
$-35.8M
$-4.3M
Q3 24
$-39.0M
$-5.7M
Q2 24
$-20.2M
$-5.0M
Q1 24
$-31.2M
$-20.2M
Free Cash Flow
EYPT
EYPT
QTRX
QTRX
Q4 25
$-66.0M
$-16.5M
Q3 25
$-60.2M
$-41.9M
Q2 25
$-63.8M
$-6.4M
Q1 25
$-53.4M
$-15.1M
Q4 24
$-36.2M
$-4.7M
Q3 24
$-40.6M
$-6.6M
Q2 24
$-21.1M
$-6.5M
Q1 24
$-32.4M
$-20.7M
FCF Margin
EYPT
EYPT
QTRX
QTRX
Q4 25
-10667.7%
-37.7%
Q3 25
-6226.9%
-104.2%
Q2 25
-1196.5%
-26.3%
Q1 25
-218.4%
-49.9%
Q4 24
-312.7%
-13.4%
Q3 24
-385.8%
-18.4%
Q2 24
-222.4%
-19.1%
Q1 24
-277.0%
-64.5%
Capex Intensity
EYPT
EYPT
QTRX
QTRX
Q4 25
159.3%
0.2%
Q3 25
82.6%
1.7%
Q2 25
22.9%
3.2%
Q1 25
1.1%
4.1%
Q4 24
3.3%
1.2%
Q3 24
15.0%
2.4%
Q2 24
9.5%
4.7%
Q1 24
10.2%
1.6%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EYPT
EYPT

Segment breakdown not available.

QTRX
QTRX

Products$29.2M67%
Consumable And Other Products$12.7M29%
Service Type Warranties$1.7M4%

Related Comparisons